Poor
Majority Misaligned
Patient Risk:
Moderate
Summary
Several mechanism and clinical-use claims were made without support in the provided diltiazem hydrochloride extended-release capsule labeling excerpts, and at least one adverse-reaction claim is not supported by the provided adverse-reaction data. Some claims are broadly consistent (hypertension indication; diltiazem is a calcium channel blocker) but overall alignment is poor due to unsupported/partially unsupported specifics.
Category Scores
Accurate Statements
Diltiazem is a calcium channel blocker.
Clinical Pharmacology indicates therapeutic effects relate to inhibition of calcium ion influx in cardiac and vascular smooth muscle.
Both diltiazem and lisinopril are primarily prescribed for hypertension (high blood pressure).
Provided label excerpt: diltiazem hydrochloride extended-release capsules are indicated for treatment of hypertension; may be used alone or in combination with other antihypertensive medications. (Lisinopril claims cannot be supported from provided diltiazem label excerpts.)
Unsupported Statements
Diltiazem relaxes and widens blood vessels, lowering blood pressure.
While the label excerpt states hypertension effects are related to relaxation of vascular smooth muscle and decrease in peripheral vascular resistance, the specific framing 'widens blood vessels' is not explicitly stated in the provided label text.
Diltiazem slows down the heart rate.
The label excerpt includes 'reductions in heart rate' for angina and decreases in sinoatrial and atrioventricular conduction, but it does not explicitly state 'slows down the heart rate' as a general effect statement in the provided excerpts.
Diltiazem may also be used to treat certain heart rhythm disorders, like angina (chest pain).
The provided diltiazem label excerpt supports indications for chronic stable angina and angina due to coronary artery spasm; it does not support the claim that angina is a 'heart rhythm disorder' or that diltiazem is used for 'heart rhythm disorders' in the provided text.
Common side effects of diltiazem can include swelling of the ankles or feet, headache, dizziness, constipation, and nausea.
The provided adverse reactions excerpt supports headache and dizziness and includes edema (ankle/feet swelling is consistent with edema). However, constipation and nausea are not included in the provided 'most common adverse reactions' list in the excerpts.
Doctors may prescribe both diltiazem and lisinopril to achieve better blood pressure control.
The diltiazem label excerpt says it may be used alone or in combination with other antihypertensive medications, but the specific pairing with lisinopril and intent 'to achieve better blood pressure control' is not explicitly supported in the provided text.
The decision to combine medications depends on an individual's specific health condition and response to treatment.
Not specified in the provided diltiazem labeling excerpts.
Contradictions
Low
AI Statement
Common side effects of diltiazem can include swelling of the ankles or feet, headache, dizziness, constipation, and nausea.
Label Reference
Provided Adverse Reactions excerpt: only headache, dizziness, bradycardia, AV block first degree, edema, asthenia are listed as most common; constipation and nausea are not included in the provided most-common table.
Important Omissions
Key safety details relevant to diltiazem (e.g., contraindications such as sick sinus syndrome/AV block/hypotension; warnings about AV conduction effects, symptomatic hypotension, and worsening congestive heart failure) were not mentioned in the AI response.
Importance:
Moderate
Diltiazem adverse reactions supported by the provided excerpt such as bradycardia and AV block first degree were not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or partially unsupported claims (e.g., constipation/nausea as common adverse effects; mischaracterization of 'heart rhythm disorders') and omission of key contraindications/warnings could contribute to misunderstanding of risks or appropriate use, though the response did not assert specific contraindication-violating dosing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Majority Misaligned
Primary Issue
Several safety/clinical-use claims are not supported by the provided diltiazem label excerpts, including 'heart rhythm disorders' framing and listing constipation/nausea as common adverse effects; key warnings/contraindications are omitted.
Suggested Improvement
Restrict claims to the provided labeling excerpts (indications: hypertension; chronic stable angina and angina due to coronary artery spasm; supported common adverse reactions: headache, dizziness, bradycardia, AV block first degree, edema, asthenia). Avoid describing use for 'heart rhythm disorders' unless supported by the provided label text. Add major contraindications and warnings (AV conduction risks, symptomatic hypotension, worsening congestive heart failure) when making safety-related statements.